WHY IT MATTERS: Patients seeking cannabinoid-based treatments may find that the medicines with the strongest clinical evidence available elsewhere in the world remain inaccessible in the U.S. not because of safety concerns, but because of who is permitted to conduct the research in the first place. CLINICAL OVERVIEW: The United States maintains a uniquely fragmented regulatory environment for cannabis research, where federal scheduling under the Controlled Substances Act creates structural barriers that foreign operators and even domestic companies struggle to navigate when developing cannabinoid-based medicines. Unlike pharmaceuticals that can be studied and approved through relatively standardized international pathways, cannabis research in the U.S.